aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
29. Januar 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
18. Januar 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
13. November 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
09. November 2023 16:00 ET
|
aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated...
aTyr Pharma to Present at November Investor Conferences
01. November 2023 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces that it will present at two investor conferences in November 2023.
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
31. Oktober 2023 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces that it has dosed the first patient in its Phase 2 EFZO-CONNECT study of efzofitimod in patients with SSc-ILD.
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
11. September 2023 08:00 ET
|
aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
24. August 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
09. August 2023 16:00 ET
|
aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the...
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis
22. Juni 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...